Diaceutics' growth reflects the rise in diagnostic use in enabling therapies | Diaceutics

Diaceutics’ growth reflects the rise in diagnostic use in enabling therapies

April 13th, 2017

Since inception, Diaceutics has been involved in more than 200 drug launches and currently has a 60% share in the top 10 global markets. We currently count 26 out of the world’s top 30 pharmaceutical companies as clients and provide oversight, analysis and tracking of testing in 23 markets, every year helping 48,000 cancer patients access the personalized medicine that is right for them.

Our knowledge of diagnostic commercialization has allowed us to develop as a company in line with the increasing use of diagnostics and pharma’s understanding of the importance of testing. To ensure we support and guide our pharma clients we bring global experts from the laboratory, diagnostic and pharmaceutical industries into the team.

This team is set to increase considerably as we lead the way in integrating diagnostic testing into drug launch programmes. [php slug=GetLink param=”id=6300&title=Diaceutics has just announced 30 new jobs&useTitle=true”] which will see us grow to 100 people by end of 2018, reflecting the company’s growing international influence as we expand in key markets such as the US, EU, Asia and South America.

To help facilitate the growth in its business, Diaceutics recently strengthened its senior management team with the addition of three domain experts:

Dr. Juliesta E. Sylvester is a new managing director of data and analytics, and will be developing our analytics platform to generate actionable insights for partners and clients.

 

Dr. Peter Krein is a new managing director of client operations and will promote business growth through new strategic initiatives.

 

Dr. Merdol Ibrahim will lead the global Laboratory Implementation team, building peer relationships with laboratories and pharma clients to support the launch and long-term adoption of diagnostic biomarkers and associated technologies.

 

Peter Keeling, CEO, Diaceutics, said: “Testing is now at the heart of pharmaceutical companies’ ability to identify the right patients for their new therapies. We are uniquely positioned to provide the global testing perspective that allows this identification and treatment of patients who will benefit from specific and often life-saving drugs.”

With a market forecast to grow from $1.4bn today to $4bn by 2020, Diaceutics is set to transform an industry model by enabling pharmaceutical companies to accelerate their market penetration and achieve a better return on new therapies.

Webinars & Podcasts

August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
April 20th, 2018
Podcast: PM Readiness Report 2018
Peter Keeling discusses the landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value.
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Publications

September 11th, 2018
BRAF mutation testing in melanoma – Poster presented at European Congress of Pathology 2018
BRAF mutation testing in melanoma: a study including Austria, Germany and UK, highlighting concordance for current technologies, and potential requirement of more sensitive technologies in future applications.
August 3rd, 2018
A Way Forward: Leveraging Advanced Diagnostic Testing to Unlock the Value of Precision Medicine
Read about how advanced diagnostic testing, ensuring that right patient gets the right therapy, at the right time, particularly with respect to therapies where the test result determines whether or not the therapy should be used (precision medicin...
View all publications
Facebook
Twitter
YouTube
LinkedIn